ArticleArthritis research & therapy2017
Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.
Article in Arthritis research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Meta-Analysis of the Incidence and Influencing Factors of Malignant Tumors in Patients with Rheumatoid Arthritis.Journal of epidemiology and global health · 2026Pooled it
- Associated factors of osteoporosis in Chinese patients with rheumatoid arthritis: A systematic review and meta-analysis.Journal of the Chinese Medical Association : JCMA · 2024Pooled it
- The Efficacy of Antioxidative Stress Therapy on Oxidative Stress Levels in Rheumatoid Arthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Oxidative medicine and cellular longevity · 2021Pooled it
- Trial
- A Study on the Safety, Pharmacokinetics, and Pharmacodynamics of H018 Tablets, a Selective JAK1 Inhibitor, Upon Single- and Multiple-Dose Administration in Chinese Healthy Subjects.Clinical drug investigation · 2026Trial
- Correlation Analysis of Coagulation and Platelet Parameters with Clinical Outcomes in Rheumatoid Arthritis Patients and the Interventional Effect of Jianpi Huashi Tongluo Formula - Xinfeng Capsule: A Post Hoc Analysis Based on an Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
- Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients.Journal of orthopaedic surgery and research · 2019Trial
- Synergistic effects of ambient particulate matter and extreme weather events on arthritis risk: a prospective cohort study.BMC public health · 2026Article
- Evolving Characteristics of Rheumatoid Arthritis Patients Receiving Primary Hip or Knee Arthroplasty: A 21-Year Single-Center Trend Analysis (2002-2022).Orthopaedic surgery · 2026Article
- Clinical characteristics and risk factors of severe myelosuppression in rheumatoid arthritis patients with csDMARD non-adherence: a case series.Frontiers in pharmacology · 2026Review
- Machine learning reveals targets ofFrontiers in immunology · 2026Article
- Knowledge attitude and practice of older adults rheumatoid arthritis patients regarding disease management in a cross-sectional study.Frontiers in public health · 2026Article
- Exploring the comorbidity mechanisms of ITGB2 in rheumatoid arthritis and membranous nephropathy through integrated bioinformatics analysis.Renal failure · 2025Article
- [Molecular mechanism ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Improving Clinical Management and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis in China via Real-world Evidence (IMPROVE Study): A Multicenter Prospective Cohort Study.Advances in therapy · 2025Article
- Predictive value of insulin resistance metabolic score for cardiovascular disease in Chinese arthritis patients: a prospective cohort study.Rheumatology (Oxford, England) · 2025Article
- Tongue feature-based model for assessing disease activity in patients with rheumatoid arthritis.Frontiers in pharmacology · 2025Article
- Association between age at first birth and risk of rheumatoid arthritis in women: Evidence from NHANES 2011-2020.PloS one · 2025Article
- Article
- Trends in rheumatoid arthritis burden in China and globally, 1990-2021: A longitudinal study based on the GBD database.PloS one · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundRheumatoid arthritis patients are at higher risk of developing comorbidities. The main objective of this study was to evaluate the prevalence of major comorbidities in Chinese rheumatoid arthritis patients. We also aimed to identify factors associated with these comorbidities.
methodsBaseline demographic, clinical characteristics and comorbidity data from RA patients enrolled in the Chinese Registry of rhEumatoiD arthrITis (CREDIT) from Nov 2016 to August 2017 were presented and compared with those from five other registries across the world. Possible factors related to three major comorbidities (cardiovascular disease, fragility fracture and malignancy) were identified using multivariate logistic regression analyses.
resultsA total of 13,210 RA patients were included (80.6% female, mean age 52.9 years and median RA duration 4.0 years). Baseline prevalence rates of major comorbidities were calculated: CVD, 2.2% (95% CI 2.0-2.5%); fragility fracture, 1.7% (95% CI 1.5-1.9%); malignancy, 0.6% (95% CI 0.5-0.7%); overall major comorbidities, 4.2% (95% CI 3.9-4.6%). Advanced age was associated with all comorbidities. Male gender and disease duration were positively related to CVD. Female sex and longer disease duration were potential risk factors for fragility fractures. Ever use of methotrexate (MTX) was negatively related to baseline comorbidities.
conclusionsPatients with rheumatoid arthritis in China have similar prevalence of comorbidities with other Asian countries. Advanced age and long disease duration are possible risk factors for comorbidities. On the contrary, MTX may protect RA patients from several major comorbidities, supporting its central role in the management of rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.